0000947871-21-000186.txt : 20210212 0000947871-21-000186.hdr.sgml : 20210212 20210212171023 ACCESSION NUMBER: 0000947871-21-000186 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20210212 DATE AS OF CHANGE: 20210212 GROUP MEMBERS: ORBIMED CAPITAL LLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Theravance Biopharma, Inc. CENTRAL INDEX KEY: 0001583107 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-88552 FILM NUMBER: 21629389 BUSINESS ADDRESS: STREET 1: UGLAND HOUSE, SOUTH CHURCH STREET CITY: GEORGE TOWN, GRAND CAYMAN STATE: E9 ZIP: KY1-1104 BUSINESS PHONE: 650-808-6000 MAIL ADDRESS: STREET 1: UGLAND HOUSE, SOUTH CHURCH STREET CITY: GEORGE TOWN, GRAND CAYMAN STATE: E9 ZIP: KY1-1104 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ORBIMED ADVISORS LLC CENTRAL INDEX KEY: 0001055951 IRS NUMBER: 133976876 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 601 LEXINGTON AVENUE STREET 2: 54TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 739-6400 MAIL ADDRESS: STREET 1: 601 LEXINGTON AVENUE STREET 2: 54TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 SC 13G 1 ss192046_sc13g.htm SCHEDULE 13G
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

SCHEDULE 13G

     

Under the Securities Exchange Act of 1934

 

     

 

Theravance Biopharma, Inc.
(Name of Issuer)

 

 

Common Stock, $0.0001 par value per share
(Title of Class of Securities)

 

 

G8807B106
(CUSIP Number)

 

 

December 31, 2020
(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

x Rule 13d-1(b)

o Rule 13d-1(c)

o Rule 13d-1(d)

 

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 
   

 

CUSIP No. G8807B106  SCHEDULE 13G Page 2 of 8 Pages
         
1

NAME OF REPORTING PERSONS

 

OrbiMed Capital LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) o

(b) o

 
3

SEC USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5

SOLE VOTING POWER

 

5,544,212

6

SHARED VOTING POWER

 

7

SOLE DISPOSITIVE POWER

 

5,544,212

8

SHARED DISPOSITIVE POWER

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

5,544,212

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

o
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.67%

12

TYPE OF REPORTING PERSON

 

IA

 

 

   

 

CUSIP No. G8807B106  SCHEDULE 13G Page 3 of 8 Pages
         
1

NAME OF REPORTING PERSONS

 

OrbiMed Advisors LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) o

(b) o

 
3

SEC USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

674,898

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

674,898

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

674,898

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

o
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

1.05%

12

TYPE OF REPORTING PERSON

 

IA

 

 

 

   

 

CUSIP No.  G8807B106  SCHEDULE 13G Page 4 of 8 Pages

 

Item 1.   (a) Name of Issuer:

Theravance Biopharma, Inc.

    (b) Address of Issuer’s Principal Executive Offices:

Ugland House, South Church Street

Georgetown, Grand Cayman KY1-1104

Item 2.   (a) Name of Person Filing:

OrbiMed Capital LLC

OrbiMed Advisors LLC

    (b) Address of Principal Business Office:

601 Lexington Avenue, 54th Floor

New York, NY 10022

    (c) Citizenship:

Please refer to Item 4 on each cover page for each Reporting Person.

    (d) Title of Class of Securities:

Common Stock, $0.0001 par value per share

    (e) CUSIP No.:

G8807B106

 

 

 

 

 

 

   

 

CUSIP No. G8807B106  SCHEDULE 13G Page 5 of 8 Pages

 

 

Item 3.      

OrbiMed Advisors LLC (“Advisors”) and OrbiMed Capital LLC (“Capital”) are investment advisors in accordance with ss.240.13d-1(b)(1)(ii)(E).

 

 

 

 

 

 

 

 

 

   

 

CUSIP No. G8807B106  SCHEDULE 13G Page 6 of 8 Pages

 

 

Item 4. Ownership:

Information with respect to the Reporting Person’s ownership as of December 31, 2020 is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

 

The reporting persons are holding 9.72% of the shares in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. No one such other person’s interest in the securities whose ownership is reported here relates to more than five percent of the class. Advisors and Capital exercise investment and voting power over the shares through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Common Stock reported herein.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

 

Not Applicable.

Item 9. Notice of Dissolution of Group.

 

Not Applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

 

 

 

 

 

   

 

CUSIP No. G8807B106  SCHEDULE 13G Page 7 of 8 Pages

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 12, 2021

 

 

       
  OrbiMed Advisors LLC
       
       
  By: /s/ Jonathan T. Silverstein
    Name:  Jonathan T. Silverstein
    Title:  Member
       
  By: /s/ Sven H. Borho
    Name:  Sven H. Borho
    Title: Member
       
  By: /s/ Carl L. Gordon
    Name:  Carl L. Gordon
    Title:  Member

 

       
 

OrbiMed Capital LLC

       
       
  By: /s/ Jonathan T. Silverstein
    Name:  Jonathan T. Silverstein
    Title:  Member
       
  By: /s/ Sven H. Borho
    Name:  Sven H. Borho
    Title: Member
       
  By: /s/ Carl L. Gordon
    Name:  Carl L. Gordon
    Title:  Member

 

 

 

 

   
EX-99.A 2 ss192046_ex99a.htm JOINT FILING AGREEMENT

 

CUSIP No. G8807B106  SCHEDULE 13G Page 8 of 8 Pages

 

 

EXHIBIT A

JOINT FILING AGREEMENT

 

The undersigned hereby agree that the Statement on this Schedule 13G dated February 12, 2021 (the “Schedule 13G”), with respect to the Common Stock, par value $0.0001 per share, of Theravance Biopharma, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of February 12, 2021.

       
  OrbiMed Advisors LLC
       
       
  By: /s/ Jonathan T. Silverstein
    Name:  Jonathan T. Silverstein
    Title:  Member
       
  By: /s/ Sven H. Borho
    Name:  Sven H. Borho
    Title: Member
       
  By: /s/ Carl L. Gordon
    Name:  Carl L. Gordon
    Title:  Member
       

 

       
 

OrbiMed Capital LLC

       
       
  By: /s/ Jonathan T. Silverstein
    Name:  Jonathan T. Silverstein
    Title:  Member
       
  By: /s/ Sven H. Borho
    Name:  Sven H. Borho
    Title: Member
       
  By: /s/ Carl L. Gordon
    Name:  Carl L. Gordon
    Title:  Member